Charlotte F Kweldam1, Mark F Wildhagen2,3, Chris H Bangma2, Geert J L H van Leenders1. 1. Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands. 2. Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands. 3. Department of Research Office Sophia, Erasmus Medical Center, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: To assess the metastasis-free survival (MFS) and disease-specific survival (DSS) in men with Gleason score ≤6 prostate cancer at radical prostatectomy (RP). PATIENTS AND METHODS: We included 1101 consecutive RP patients operated between March 1985 to July 2013 at a single institution. The outcome variables were MFS and DSS. The postoperative survival was estimated by the Kaplan-Meier method. RESULTS: The Gleason score distribution of the study population (1101 patients) was Gleason score ≤6 (449, 41%), Gleason score 3 + 4 = 7 (436, 40%), Gleason score 4 + 3 = 7 (99, 9%) and Gleason score 8-10 (117, 11%). The median (interquartile range) postoperative follow-up was 100 (48-150) months. During follow-up 197 men (18%) died, of whom 42 (3.8%) died from prostate cancer-related causes. In all, 19/1101 patients (1.7%) had documented lymph node metastasis at the time of RP: none with Gleason score ≤6, seven with Gleason score 3 + 4 = 7 (1.6%), six with Gleason score 4 + 3 = 7 (6.1%) and six with Gleason score 8-10 (5.1%). Distant metastasis occurred in 56/1101 patients (5.1%): none with Gleason score ≤6, 23 with Gleason score 3 + 4 = 7 (5.3%), 17 with Gleason score 4 + 3 = 7 (17%) and 16 with Gleason score 8-10 (14%). Disease-specific death, stratified per Gleason-score group was: none in ≤6, 16 (3.7%) in 3 + 4 = 7, 16 (16%) in 4 + 3 = 7 and 10 (8.5%) in 8-10 group. CONCLUSION: No metastasis or disease-specific death were seen in men with Gleason score ≤6 prostate cancer at RP, showing the negligible potential to metastasise in this large subgroup of patients with prostate cancer.
OBJECTIVES: To assess the metastasis-free survival (MFS) and disease-specific survival (DSS) in men with Gleason score ≤6 prostate cancer at radical prostatectomy (RP). PATIENTS AND METHODS: We included 1101 consecutive RP patients operated between March 1985 to July 2013 at a single institution. The outcome variables were MFS and DSS. The postoperative survival was estimated by the Kaplan-Meier method. RESULTS: The Gleason score distribution of the study population (1101 patients) was Gleason score ≤6 (449, 41%), Gleason score 3 + 4 = 7 (436, 40%), Gleason score 4 + 3 = 7 (99, 9%) and Gleason score 8-10 (117, 11%). The median (interquartile range) postoperative follow-up was 100 (48-150) months. During follow-up 197 men (18%) died, of whom 42 (3.8%) died from prostate cancer-related causes. In all, 19/1101 patients (1.7%) had documented lymph node metastasis at the time of RP: none with Gleason score ≤6, seven with Gleason score 3 + 4 = 7 (1.6%), six with Gleason score 4 + 3 = 7 (6.1%) and six with Gleason score 8-10 (5.1%). Distant metastasis occurred in 56/1101 patients (5.1%): none with Gleason score ≤6, 23 with Gleason score 3 + 4 = 7 (5.3%), 17 with Gleason score 4 + 3 = 7 (17%) and 16 with Gleason score 8-10 (14%). Disease-specific death, stratified per Gleason-score group was: none in ≤6, 16 (3.7%) in 3 + 4 = 7, 16 (16%) in 4 + 3 = 7 and 10 (8.5%) in 8-10 group. CONCLUSION: No metastasis or disease-specific death were seen in men with Gleason score ≤6 prostate cancer at RP, showing the negligible potential to metastasise in this large subgroup of patients with prostate cancer.
Authors: Oleksandr N Kryvenko; Kirill Lyapichev; Felix M Chinea; Nachiketh Soodana Prakash; Alan Pollack; Mark L Gonzalgo; Sanoj Punnen; Merce Jorda Journal: Am J Surg Pathol Date: 2016-08 Impact factor: 6.394
Authors: Jan Herden; Lena Ansmann; Nicole Ernstmann; Dietrich Schnell; Lotharh Weißbac Journal: Dtsch Arztebl Int Date: 2016-05-13 Impact factor: 5.594
Authors: Chirag Doshi; Michael Vacchio; Kristopher Attwood; Christine Murekeyisoni; Diana C Mehedint; Shervin Badkhshan; Gissou Azabdaftari; Norbert Sule; Khurshid A Guru; James L Mohler; Eric C Kauffman Journal: Prostate Date: 2016-02-16 Impact factor: 4.104
Authors: Lionne D F Venderbos; Monique J Roobol; Chris H Bangma; Roderick C N van den Bergh; Leonard P Bokhorst; Daan Nieboer; Rebecka Godtman; Jonas Hugosson; Theodorus van der Kwast; Ewout W Steyerberg Journal: World J Urol Date: 2015-07-10 Impact factor: 4.226
Authors: René Böttcher; Charlotte F Kweldam; Julie Livingstone; Emilie Lalonde; Takafumi N Yamaguchi; Vincent Huang; Fouad Yousif; Michael Fraser; Robert G Bristow; Theodorus van der Kwast; Paul C Boutros; Guido Jenster; Geert J L H van Leenders Journal: BMC Cancer Date: 2018-01-02 Impact factor: 4.430
Authors: Sophie M Bruinsma; Chris H Bangma; Peter R Carroll; Michael S Leapman; Antti Rannikko; Neophytos Petrides; Mahesha Weerakoon; Leonard P Bokhorst; Monique J Roobol Journal: Nat Rev Urol Date: 2016-01-27 Impact factor: 14.432